All In Biotech

NDA 204026 · Bristol

Pomalyst

Pomalidomide · Oral · Thalidomide Analog

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Feb 8, 2013

Approved uses

5

Original approval plus efficacy supplements

Registered trials

314

56 Phase 3, 58 recruiting

FAERS reports

103,640

63,661 serious, 14,174 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM See full prescribing information for complete boxed warning EMBRYO-FETAL TOXICITY • POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects ( 4 , 5.1 , 8.1 ). • For females of reproductive potential: Exclude pregnancy before start of treatment. Prevent pregnancy during treatment by the use of 2 reliable methods of contraception ( 5.1 , 8.3 ). POMALYST is available only through a restricted program called PS-Pomalidomide REMS ( 5.2 ). VENOUS AND ARTERIAL THROMBOEMBOLISM • Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Antithrombotic...

What it is approved for

From the label in effect Feb 26, 2025.

POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). 1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Mechanism: Pomalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of pomalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of drug, substrate proteins (including Aiolos and Ikaros) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 20, 2020 Supplement 27 · Efficacy · priority review LetterLabel
  • May 14, 2020 Supplement 23 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • May 14, 2020 Supplement 24 · Efficacy · priority review OrphanLabelLetter
  • Apr 23, 2015 Supplement 6 · Efficacy OrphanLetterLabel
  • Feb 8, 2013 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewLetterLabel
4 products under this application
  • POMALYST · POMALIDOMIDE 3MG · CAPSULE, ORAL · Prescription · TE AB
  • POMALYST · POMALIDOMIDE 1MG · CAPSULE, ORAL · Prescription · TE AB
  • POMALYST · POMALIDOMIDE 4MG · CAPSULE, ORAL · Prescription · TE AB
  • POMALYST · POMALIDOMIDE 2MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Pomalidomide" as an intervention, any sponsor and status, largest first.

All 314 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • plasma cell myeloma8,169
  • death7,797
  • fatigue7,599
  • pneumonia6,387
  • off label use4,625
  • diarrhoea3,966
  • white blood cell count decreased3,709
  • neutropenia3,391
  • rash3,107
  • dyspnoea2,887
  • asthenia2,718
  • constipation2,705

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20112
20126
20131,217
20142,659
20155,383
20165,867
20176,831
20187,077
20199,195
202010,066
202113,133
202211,306
20238,275
20248,960
20258,607
20265,056

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pomalyst (Pomalidomide)

2024 spending

$2.15B

Beneficiaries

14,325

98,648 claims

Per beneficiary

$150,103

$1,094.75 per unit

View as table
YearSpending
2020$1,453,860,767
2021$1,595,079,245
2022$1,743,892,720
2023$1,709,288,465
2024$2,150,231,815

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 203 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.